Drugs in the Pipeline
Vamorolone is a first-in-class dissociative steroidal drug that retains the anti-inflammatory activity of corticosteroids but with a novel mechanism of action.
News
Dupixent single-dose prefilled pens feature a hidden needle and single-press auto-injection.
Drugs in the Pipeline
Efzofitimod is a potential first-in-class selective modulator of neuropilin-2 that is designed to downregulate innate and adaptive immune responses in inflammatory disease states.
News
The updated labeling is based on results from a safety management cohort from the ZUMA-1 study.
News
The approval was based on data from the phase 3 JADE clinical trial program, which included the JADE MONO-1, JADE MONO-2, and JADE COMPARE trials.
News
The approval was based on data from three phase 3 trials that evaluated the efficacy and safety of upadacitinib in patients 12 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.
Drugs in the Pipeline, News
The FDA's Fast Track process allows for expedited review of drugs that are expected to fill an unmet need.
News
Zolgensma is an adeno-associated virus vector-based gene therapy.
News
The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 VOYAGE trial.
Drugs in the Pipeline, News
Rilzabrutinib is an oral Bruton tyrosine kinase inhibitor currently in development for a number of immune-mediated diseases.
